Searching for a New Indication

Tibin K. Titus, Mercer University College of Pharmacy

Hypertension is a worldwide problem with its prevalence increasing in the aging population. Complications of hypertension include stroke and cardiovascular diseases. [1] Angiotensin-converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), diuretics, and calcium channel blockers are recommended as first line therapy. [2]

Sacubitril/valsartan (Entresto®) is a combination product consisting of an angiotensin receptor neprilysin inhibitor, sacubitril, and an ARB, valsartan. [3] Previous studies with sacubitril/valsartan have demonstrated significant reductions in office and ambulatory BP compared with valsartan or placebo. [4]

Continue reading


Who is at Risk for Atherosclerotic Cardiovascular Disease

Meron Mezgebe, Mercer University College of Pharmacy

Elevated cholesterol increases the risk for developing atherosclerotic cardiovascular disease (ASCVD). [1] For the monitoring of cholesterol levels the American College of Cardiology and American Heart Association (ACC/AHA) recommend an initial lipid panel of patients 21 years or older, with no clinical ASCVD, and not currently on cholesterol-lowering drugs. The ACC/AHA statin benefit group assignment is made using patients’ age, comorbidities, 10-year ASCVD risk, and lipid panel. [2] A systematic review on lipid screening of younger adults (21-39 years) found no studies directly evaluating the effects of lipid screening versus no screening in younger adults. [3] The U.S. preventative services task force (USPSTF) recommends screening for lipid disorders in men 35 years or older and women 45 years or older, unless they have increased risk of coronary heart disease. [4] Continue reading

Less-tight versus tight control of hypertension in pregnancy

Diana Lee, PharmD Candidate 2015 Mercer University College of Pharmacy

Hypertension during pregnancy occurs in approximately 10% of all pregnant women. Gestational and preexisting hypertension before 34 weeks are associated with an increased risk of perinatal and maternal complications, such as intracerebral hemorrhage, poor fetal growth and well-being. The treatment of severe hypertension during pregnancy (>160/110 mm Hg) is considered to be well established. However, the benefit of antihypertensive therapy for mild-to-moderately elevated blood pressure (< 160/110) have not been demonstrated.1 Continue reading